Huadong Medicine’s HDM1005 Receives NMPA Approval for Clinical Trials
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Huadong Medicine
Huadong Medicine’s ADC HDM2005 Granted FDA Orphan Drug Designation for MCL
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its antibody-drug conjugate (ADC) HDM2005 has...
SMPA Suspends Indobufen Procurement After Patent Infringement Verdict
Shanghai’s Sunshine Medical Procurement All-In-One (SMPA) announced the suspension of procurement for indobufen, manufactured by...
Huadong Medicine’s HDM1005 Receives NMPA Approval for OSA Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its HDM1005, a long-acting GLP-1/GIP receptor...
Huadong Medicine’s Biosimilar Tresiba Accepted by NMPA for Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its market filing for a biosimilar...
Huadong Medicine’s MediBeacon TGFR System Approved by NMPA for GFR Measurement
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received marketing approval from...
Huadong Medicine’s HDM1005 Shows Positive Results in Phase Ia/Ib Study
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced positive results from the Phase Ia/Ib study...
Huadong Medicine’s Biosimilar SaiYueXin Seeks NMPA Approval for Crohn’s Disease
Huadong Medicine Co., Ltd (SHE: 000963) announced that another indication approval filing for its SaiYueXin,...
Huadong Medicine’s Ellansé M Filing Accepted by China’s NMPA
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that its market filing for the...
Huadong Medicine’s MediBeacon TGFR System Receives FDA Marketing Clearance
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing clearance from the US...
Impact Therapeutics’ Senaparib Cleared by NMPA for Ovarian Cancer Therapy
China-based Impact Therapeutics has announced receiving marketing clearance from the National Medical Products Administration (NMPA)...
Huadong Medicine Gets FDA Nod for Phase I Study of HDM2006 in Solid Tumors
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...
Huadong Medicine’s HDM1005 Receives NMPA Approval for MAFLD/MASH Clinical Trial
Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial approval...
Huadong Medicine Partners with SynerK PharmaTech for Hypertension siRNA Drug Development
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced a strategic partnership agreement with SynerK...
Huadong Medicine’s HDM1005 Receives FDA Clearance for Heart Failure and Obesity Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...
Huadong Medicine’s Arcalyst Receives NMPA Approval for Recurrent Pericarditis Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving another indication approval from the...
Huadong Medicine’s SaiYueXin Biosimilar Accepted for Review by NMPA for Pediatric Psoriasis
Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration (NMPA)...
Huadong Medicine Receives FDA Clearance for HDM1005 Clinical Study in Obstructive Sleep Apnea
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...
Huadong Medicine’s Arcalyst Receives NMPA Approval for Cryopyrin-Associated Periodic Syndromes
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving marketing approval from the National...
Huadong Medicine’s Elahere (Mirvetuximab Soravtansine) Approved by NMPA for Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received marketing approval...